Novartis ($NVS) made history this month with the first FDA approval of a biosimilar, and now a judge's ruling has cleared the way for its launch. The drug, Zarxio, is a copy of Amgen's ($AMGN) blockbuster Neupogen, which is designed to boost white blood cell counts. Amgen sued in an effort to block Novartis from debuting its product in the U.S., but a federal judge denied its request for a temporary injunction, giving Novartis the green light to market its knockoff. More from FiercePharma